Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
Mar 18, 2024
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London
➞
Mar 18, 2024
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
➞
Mar 15, 2024
Mabwell has been included in the FTSE Russell Global Equity Index Series
➞
Mar 11, 2024
Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London
➞
Mar 07, 2024
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
➞
Mar 07, 2024
Mabwell's Expanded Access Policy for 9MW2821
➞
Mar 06, 2024
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
➞
Feb 25, 2024
FDA Grants Fast Track Designation to 9MW2821
➞
Feb 19, 2024
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
➞
Feb 18, 2024
FDA Grants Orphan Drug Designation to 9MW3011
➞
上一页
1
2
3
4
下一页